Overview

Clopidogrel Bioequivalence Study in Healthy Subjects

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study will be an open-label, randomised, three-way crossover study in healthy male and female subjects, performed at a single centre. The objective of the study is to assess the bioequivalence between one test formulation (Clopidogrel 75 mg tablet (commercial blister from KRKA) and two reference formulations (Clopidogrel 75 mg tablet [Plavix, sourced in US and Japan]).
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Clopidogrel
Ticlopidine